What guidance did Prestige Consumer Healthcare's management provide for the next earnings period?

What is the revenue and EPS growth rate for Prestige Consumer Healthcare year over year?

What is the market's earnings forecast for Prestige Consumer Healthcare next quarter?

What is Prestige Consumer Healthcare's latest dividend and current dividend yield?

What does Prestige Consumer Healthcare do and what are its main business segments?

What is Prestige Consumer Healthcare's gross profit margin?

What were the key takeaways from Prestige Consumer Healthcare’s earnings call?

What were the key takeaways from Prestige Consumer Healthcare's earnings call?

- **Revenue Resilience**: $283 million Q3 revenue, up 13% in free cash flow, despite 2.4% YoY decline driven by Clear Eyes supply issues.
- **Supply Chain Progress**: 3rd consecutive quarter of Clear Eyes supply improvement, with Pillar5 acquisition enabling internal production control.
- **Financial Strength**: $209 million free cash flow YTD, supporting $46 million share buybacks and strategic M&A.
- **Strategic Focus**: E-commerce growth, brand expansion (e.g., Compound W skin tag product), and disciplined capital allocation for long-term value.

**【CEO Summary Section】**
- Q3 2026 revenue of $283 million, slightly above forecast, driven by strong e-commerce and mass channel growth despite macro challenges.
- Sequential improvement in Clear Eyes supply for the third consecutive quarter, with further production ramp-up expected in Q4.
- Free cash flow of $209 million year-to-date, up 13%, supporting $46 million in share repurchases and Pillar5 acquisition.
- Strategic actions to enhance eye care supply chain: 2 new suppliers, Pillar5 acquisition, and new high-speed production line.
- Full-year outlook: $1.1 billion revenue, adjusted EPS of $4.54, and $245 million+ free cash flow.

**【CFO Financial Commentary】**
- Q3 revenue declined 2.4% YoY to $283.4 million, driven by Clear Eyes supply constraints and category softness in analgesics and cough/cold.
- Adjusted EBITDA margin remained stable at low 30s, with adjusted EPS of $1.14 in line with expectations.
- $10 million write-off of a supplier loan due to business closure, with limited recovery expected.
- Year-to-date free cash flow of $208.8 million, up 12.9%, with full-year target of $245 million.
- Q4 guidance: 57% adjusted gross margin, $11 million interest expense, and 24% tax rate.

**【Q&A Key Highlights】**
- **Consumer Behavior**: Channel shift to e-commerce and mass retailers offseting weakness in traditional channels; Clear Eyes supply improvement expected to accelerate demand.
- **E-commerce Growth**: Consumption up over 10% in Q3, with focus on broad product availability and pricing transparency.
- **Women's Health**: Monistat at record share, Summer's Eve stable; category volatility due to prior-year online spikes.
- **Capital Allocation**: Share buybacks ($150 million YTD) prioritized alongside M&A, with focus on brand acquisitions.
- **2027 Outlook**: Base business growth, Clear Eyes supply normalization, and potential above-algorithm growth if consumer trends stabilize.

Prestige Consumer Healthcare Inc. (PBH) Q3 2026 Earnings Call Transcript

- **Revenue Beat with Supply Constraints**: Q2 revenue of $274 million (-3.4% YoY) exceeded expectations due to Clear Eyes supply timing and e-commerce acceleration. Q3 expected to decline further due to $5 million shipment delay.
- **Clear Eyes Recovery Plan**: Two new suppliers and Pillar Five's high-speed line to improve production in Q3/Q4, with acquisition closing in Q3.
- **Strong Financial Health**: Adjusted EPS of $1.07, 10% YoY free cash flow growth to $134 million, and $110 million in share buybacks.
- **Strategic Growth Drivers**: DenTek dental guards gain 5% market share; e-commerce consumption up double digits YoY.
- **Capital Allocation Focus**: M&A (Pillar Five), share repurchases, and disciplined cost management.

**【Management Opening Remarks】**
- Thilo Terpolilli provided an overview of the call, emphasizing the business environment's challenges, including supply chain constraints, inflation, and geopolitical risks. He highlighted the importance of reviewing risk factors in SEC filings.

**【CEO Summary Section】**
- **Q2 Results**: Revenue of $274 million declined 3.4% YoY due to Clear Eyes supply constraints and lower cough/cold sales. Adjusted EPS of $1.07 beat expectations, driven by sales timing and cost control.
- **Clear Eyes Update**: Supply improvements expected in Q3 and Q4, with two new suppliers and a high-speed line at Pillar Five. Q3 revenue impact from delayed shipments estimated at $5 million.
- **E-commerce Growth**: Double-digit consumption growth, benefiting from long-term investments in digital channels.
- **DenTek Brand**: Market share in dental guards exceeds 50%, with a successful Fantasy Football marketing campaign boosting engagement.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $420 million, Non-GAAP EPS of $1.08 (up 1.9% YoY). Gross margin 55.7% (up 60bps YoY), driven by cost savings and mix improvements.
- **Cash Flow**: Free cash flow of $134 million (10% YoY increase), with $245 million+ expected for FY2026. Share buybacks of 1.6 million shares ($110 million) in H1.
- **Strategic Acquisitions**: $100 million Pillar Five acquisition expected to close in Q3, enhancing control over sterile eye care supply.

**【Q&A Key Highlights】**
- **Clear Eyes Recovery**: Sequential improvement in Q3 and Q4, with focus on regaining shelf space and consumer trust. Pillar Five's new line to support production.
- **Inventory Health**: Retail inventories stable outside e-commerce volatility; focus on service levels during peaks/valleys.
- **Women's Health Performance**: TTM growth despite quarterly noise, driven by brand positioning and innovation.
- **Capital Allocation**: Prioritize M&A (e.g., Pillar Five), share buybacks, and disciplined cash management. No immediate plans for increased A&M spend beyond current strategy.
- **Macro Environment**: Resilience in needs-based categories; no significant impact from broader consumer slowdown.

Prestige Consumer Healthcare Inc. (PBH) Q2 2026 Earnings Call Transcript

- **Q1 Miss Due to Supply Chain**: Revenue down 6.6% YoY, driven by Clear Eyes production delays and order timing shifts.
- **Pillar5 Acquisition**: $100M purchase to secure eye care supply, with Q3 production ramp-up and FY27 recovery.
- **FY26 Guidance Update**: Revenue $1.1B-$1.115B (-1.5% to -3% YoY), EPS $4.50-$4.58, free cash flow $245M+.
- **Gross Margin Resilience**: 56.2% in Q1, with FY26 target of 56.5% despite tariff headwinds.
- **International Strength**: 7% Q1 growth, with FY26 expansion driven by brand expansion and category trends.

**【CEO Summary Section】**
- Q1 2026 revenue of $249.5 million missed expectations due to a production shutdown at Clear Eyes' supplier, resulting in a 6.6% year-over-year decline.
- Acquired Pillar5 Pharma for $100 million to secure long-term eye care supply, with new production lines expected to ramp up in Q3 and Q4.
- Full year 2026 revenue guidance revised to $1.1 billion-$1.115 billion, down 1.5%-3% YoY, with Q2 revenue expected at $256 million-$259 million.
- Diluted EPS for FY26 updated to $4.50-$4.58, with Q2 EPS of $0.97.
- Free cash flow of $78 million in Q1, maintaining FY26 target of $245 million+.

**【CFO Financial Commentary】**
- Gross margin improved 150 bps to 56.2%, driven by cost savings, with FY26 gross margin expected at 56.5%.
- Advertising & marketing expenses were $35 million (14% of sales), with FY26 A&M rate expected to remain stable.
- G&A expenses at 11.4% of sales, with FY26 target of 10%.
- Tariffs now estimated at $5 million annually, with strategic actions to offset costs.
- Tax rate for FY26 expected at 24%, with interest expense benefiting from debt reduction.

**【Q&A Highlights】**
- **Retail Environment Volatility**: July saw abnormal order swings, but normalized patterns expected in H2.
- **Clear Eyes Recovery**: Pillar5 acquisition to enable Q3 production ramp-up, with full recovery by FY27.
- **International Growth**: International segment grew 7% YoY, driven by broad-based demand, with FY26 growth expected at 5%+.
- **Capital Allocation**: Share buybacks and debt reduction remain priorities, with Pillar5 acquisition funded by cash.
- **Tariff Mitigation**: Strategic actions to fully offset $5 million annual tariff impact.


Prestige Consumer Healthcare (PBH)-7 Aug 25-2026 Q1 Earnings call transcript

- **Record 2025 Results**: $1.1B revenue (+1%), $4.52 EPS (+7%), 55.8% gross margin. 
- **2026 Outlook**: $1.14-1.155B revenue (+1-2%), $4.70-4.82 EPS (+4-7%). 
- **Tariff Resilience**: $15M FY2026 impact offset by 56.5% gross margin, 80% domestic COGS. 
- **Growth Drivers**: E-commerce (>15% sales), women's health innovation (Summer's Eve, Monistat), and GI category strength. 
- **Capital Flexibility**: $245M+ FCF for M&A, buybacks, and balance sheet strength (2.4x leverage).

**【CEO Summary Section】**
- Fiscal 2025 net revenue reached $1.1 billion, up 1% YoY, driven by 5%+ growth in the International segment and strong performance in North America GI categories (e.g., Dramamine, Fleet). 
- Adjusted EPS of $4.52 (+7%) reflects gross margin expansion to 55.8% (up 30bps YoY) and disciplined capital allocation ($240M free cash flow, 2.4x leverage). 
- 2026 outlook: $1.14-1.155B revenue (+1-2% organic), $4.70-4.82 EPS (+4-7%), with $15M tariff headwind offset by 56.5% gross margin expansion.

**【CFO Financial Commentary】**
- Q4 2025 revenue $296.5M (+7% YoY), record adj. EBITDA and EPS ($1.32 vs. $1.02). 
- FY2025 e-commerce sales >15% of total, up double digits YoY. 
- 2026 A&M reinvestment at 14% of sales, G&A flat as % of sales. 
- Free cash flow >$245M, prioritizing M&A ($1B+ 4-year FCF), share buybacks ($50M+ in 2025), and balance sheet flexibility.

**【Key Q&A Highlights】**
- **Tariff Mitigation**: $15M FY2026 impact offset via dual sourcing, cost savings, and surgical pricing. 80% COGS from domestic suppliers. 
- **Clear Eyes Recovery**: 2 new suppliers coming online in 2026, Q2+ shipment normalization. 
- **Women's Health Innovation**: Summer's Eve Whole Body Deodorant, Monistat Maintain Kit drive 2Q+ growth. 
- **Capital Allocation**: M&A prioritized over debt reduction; $50M+ share buybacks in 2025.

Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript

- **Record Financials**: Q3 2025 EPS of $1.22 (+15% YoY) and $290M sales beat expectations, fueled by international growth and cost control.
- **Cash Flow Strength**: $240M+ free cash flow enables debt reduction to 2.5x leverage and strategic M&A flexibility.
- **Supply Chain Recovery**: Clear Eyes production aligns with sales, with incremental supply improvements expected in 2026.
- **Margin Expansion**: Q4 gross margin target of 57% reflects cost-saving initiatives; long-term EBITDA margin maintained at low-30s.
- **Strategic Growth**: Hydralyte international expansion, Fleet oral laxatives, and Dramamine stress-related products drive diversified growth.

**【CEO Opening Remarks】**
- Q3 2025 net sales reached $290 million (+2.7% YoY), driven by strong international growth (Hydralyte) and broad-based North American category expansion.
- Record EPS of $1.22 (+15% YoY) reflects disciplined capital allocation, reduced interest expense, and share buybacks.
- Free cash flow of $184.9M (up 5% YoY) supports debt reduction (variable term loan to $0) and strategic flexibility.

**【CFO Financial Highlights】**
- EBITDA margin maintained at low-30s, with Q3 gross margin stabilization after Clear Eyes supply chain costs.
- Full-year free cash flow guidance reaffirmed at $240M+; leverage ratio improved to 2.5x.
- 2025 revenue outlook: $1.128B-$1.132B (1% organic growth); adjusted EPS $4.5 vs. prior $4.45.

**【Q&A Key Takeaways】**
- **Clear Eyes Recovery**: Q4 production levels to match sales, with gradual supply chain improvements expected in H2 2026.
- **Gross Margin Outlook**: Q4 57% gross margin (vs. 55.2% first nine months) driven by cost-saving initiatives.
- **Tariff Resilience**: 90%+ manufacturing in U.S. mitigates inflation risks; agile response strategy in place.
- **M&A Pipeline**: Disciplined approach to acquisitions; $40M in share buybacks YTD with optionality for further repurchases.
- **Brand Momentum**: Hydralyte international expansion, Dramamine stress-related products, and Fleet oral laxatives driving long-term growth.

Actual											0.82	0.86	0.78	0.81	0.79	1.14	1.02	0.99	0.91	1.09	1.02	1.04	1.07	1.06	1.07	1.06	1.02	0.9	1.09	1.22	1.32	0.95	1.07	1.14
Forecast											0.7357	0.7	0.7171	0.7671	0.7843	0.8667	0.9867	0.8833	0.8867	1.0383	1.0017	1.012	1.0398	1.0094	1.0673	1.0409	1.1391	0.8594	1.0846	1.1751	1.2984	0.9999	0.9696	1.1445
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+11.46%	+22.86%	+8.77%	+5.59%	+0.73%	+31.53%	+3.37%	+12.08%	+2.63%	+4.98%	+1.83%	+2.77%	+2.90%	+5.01%	+0.25%	+1.83%	-10.46%	+4.72%	+0.50%	+3.82%	+1.66%	-4.99%	+10.35%	-0.39%

PBH

PBH fundamentals

PBH Q3 2026 Earnings

Earnings Call

You can ask Aime

PBH

PBH fundamentals

PBH Q3 2026 Earnings

Earnings Call

PBH Earnings Call Summary for Q3/20268:30 AM on Feb 5, 2026

PBH Earnings Call Summary for Q2/20268:30 AM on Nov 6, 2025

PBH Earnings Call Summary for Q1/20268:30 AM on Aug 7, 2025

PBH Earnings Call Summary for Q4/20258:30 AM on May 8, 2025

PBH Earnings Call Summary for Q3/20258:30 AM on Feb 6, 2025

You can ask Aime